Fisher & Paykel Healthcare Price Target Raised to NZ$41.20 by Morgan Stanley
Fisher & Paykel Healthcare Price Target Raised to NZ$41.20 by Morgan Stanley
Morgan Stanley has raised its price target for Fisher & Paykel Healthcare shares by 3% to NZ$41.20, reflecting confidence in the company's strong performance and growth prospects.
Analyst Outlook and Market Impact
The investment bank cites the company's leading position in the healthcare equipment sector and innovative product portfolio as key drivers. The new target represents an increase from the previous estimate.
Fisher & Paykel Healthcare is known for critical care products such as respiratory devices and patient monitors. Its R&D investments and global expansion strategy have attracted analyst attention.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.